A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Rhegmatogenous Retinal Detachment
Proliferative Vitreoretinopathy

Interventions

DRUG: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
DRUG: Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud

Sponsor

Wills Eye